XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up
This study aimed to analyze the surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of operated uncontrolled glaucoma. Eyes that received XEN Gel Stent placement from December 2014 to October...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2021/2321922 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524675201466368 |
|---|---|
| author | Katarzyna Lewczuk Joanna Konopińska Joanna Jabłońska Jacek Rudowicz Patrycja Laszewicz Zofia Mariak Marek Rękas |
| author_facet | Katarzyna Lewczuk Joanna Konopińska Joanna Jabłońska Jacek Rudowicz Patrycja Laszewicz Zofia Mariak Marek Rękas |
| author_sort | Katarzyna Lewczuk |
| collection | DOAJ |
| description | This study aimed to analyze the surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of operated uncontrolled glaucoma. Eyes that received XEN Gel Stent placement from December 2014 to October 2019 were retrospectively investigated. Intraocular pressure (IOP) change, best-corrected visual acuity (BCVA), change in glaucoma medications, frequency of slit lamp revision procedures, and frequency of secondary glaucoma surgeries were the primary outcomes. Seventy-two eyes of 72 subjects were included in the study: 32 (44%) men and 40 (56%) women. The follow-up period ranged from 1 to 50 months (median, 26.13 months). The mean IOP before surgery was 24.82 ± 8.03 mmHg and decreased to 17.45 ± 5.84 mmHg at the end of the study (mean difference [MD] = −7.48, 95% confidence interval [CI]: −10.04, −4.93; p<0.001). The mean decrease from baseline was 23%. BCVA before surgery was 0.38 ± 0.30, and that at the end of the follow-up period improved to 0.47 ± 0.37, MD = 0.09, 95% CI: 0.04, 0.13; p<0.001. Additional procedures (fluorouracil injection and bleb needling) were performed in 11/72 patients (15%). Further glaucoma surgery was necessary for 23.9% of the patients. XEN Gel Stent implantation is both safe and reasonably effective for lowering IOP in operated uncontrolled glaucoma patients. |
| format | Article |
| id | doaj-art-fa4a78b453cd46669c0e563790a48c91 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-fa4a78b453cd46669c0e563790a48c912025-02-03T05:47:39ZengWileyJournal of Ophthalmology2090-004X2090-00582021-01-01202110.1155/2021/23219222321922XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-UpKatarzyna Lewczuk0Joanna Konopińska1Joanna Jabłońska2Jacek Rudowicz3Patrycja Laszewicz4Zofia Mariak5Marek Rękas6Department of Ophthalmology, Military Institute of Medicine, Warsaw, PolandDepartment of Ophthalmology, Medical University in Bialystok, M. Sklodowska-Curie 24A STR, 15-276 Bialystok, PolandDepartment of Ophthalmology, Military Institute of Medicine, Warsaw, PolandDepartment of Ophthalmology, Military Institute of Medicine, Warsaw, PolandDepartment of Ophthalmology, Military Institute of Medicine, Warsaw, PolandDepartment of Ophthalmology, Medical University in Bialystok, M. Sklodowska-Curie 24A STR, 15-276 Bialystok, PolandDepartment of Ophthalmology, Military Institute of Medicine, Warsaw, PolandThis study aimed to analyze the surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of operated uncontrolled glaucoma. Eyes that received XEN Gel Stent placement from December 2014 to October 2019 were retrospectively investigated. Intraocular pressure (IOP) change, best-corrected visual acuity (BCVA), change in glaucoma medications, frequency of slit lamp revision procedures, and frequency of secondary glaucoma surgeries were the primary outcomes. Seventy-two eyes of 72 subjects were included in the study: 32 (44%) men and 40 (56%) women. The follow-up period ranged from 1 to 50 months (median, 26.13 months). The mean IOP before surgery was 24.82 ± 8.03 mmHg and decreased to 17.45 ± 5.84 mmHg at the end of the study (mean difference [MD] = −7.48, 95% confidence interval [CI]: −10.04, −4.93; p<0.001). The mean decrease from baseline was 23%. BCVA before surgery was 0.38 ± 0.30, and that at the end of the follow-up period improved to 0.47 ± 0.37, MD = 0.09, 95% CI: 0.04, 0.13; p<0.001. Additional procedures (fluorouracil injection and bleb needling) were performed in 11/72 patients (15%). Further glaucoma surgery was necessary for 23.9% of the patients. XEN Gel Stent implantation is both safe and reasonably effective for lowering IOP in operated uncontrolled glaucoma patients.http://dx.doi.org/10.1155/2021/2321922 |
| spellingShingle | Katarzyna Lewczuk Joanna Konopińska Joanna Jabłońska Jacek Rudowicz Patrycja Laszewicz Zofia Mariak Marek Rękas XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up Journal of Ophthalmology |
| title | XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up |
| title_full | XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up |
| title_fullStr | XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up |
| title_full_unstemmed | XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up |
| title_short | XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up |
| title_sort | xen glaucoma implant for the management of operated uncontrolled glaucoma results and complications during a long term follow up |
| url | http://dx.doi.org/10.1155/2021/2321922 |
| work_keys_str_mv | AT katarzynalewczuk xenglaucomaimplantforthemanagementofoperateduncontrolledglaucomaresultsandcomplicationsduringalongtermfollowup AT joannakonopinska xenglaucomaimplantforthemanagementofoperateduncontrolledglaucomaresultsandcomplicationsduringalongtermfollowup AT joannajabłonska xenglaucomaimplantforthemanagementofoperateduncontrolledglaucomaresultsandcomplicationsduringalongtermfollowup AT jacekrudowicz xenglaucomaimplantforthemanagementofoperateduncontrolledglaucomaresultsandcomplicationsduringalongtermfollowup AT patrycjalaszewicz xenglaucomaimplantforthemanagementofoperateduncontrolledglaucomaresultsandcomplicationsduringalongtermfollowup AT zofiamariak xenglaucomaimplantforthemanagementofoperateduncontrolledglaucomaresultsandcomplicationsduringalongtermfollowup AT marekrekas xenglaucomaimplantforthemanagementofoperateduncontrolledglaucomaresultsandcomplicationsduringalongtermfollowup |